Immunovant, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IMVT | ROIV | 6IB.F | ABCL | DNTH | IOVA | |
|---|---|---|---|---|---|---|
| Market cap | 6.18B | 27.61B | 17.27B | 3.98B | 4.80B | 3.94B |
| P/E (TTM) | — | — | 123.8 | — | — | — |
| Forward P/E | -10.9 | -27.5 | — | -16.1 | -18.6 | -44.4 |
| Price/book | 8.4 | 6.5 | 6.2 | 4.2 | 7.5 | 5.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +23.05% | +78.15% | −7.55% | +159.70% | +145.18% | +387.85% |
| Today | +2.96% | +6.08% | +3.42% | +0.82% | +3.76% | −1.47% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IMVT news ›Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunovant (IMVT) and Oruka Therapeutics (ORKA) with bullish sentiments. H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on…
Immunovant: Batoclimab 2.0 Bull Case Flawed By Mixed Data, Competitive Threats
Immunovant's IMVT-1402 aims to deliver best-in-class FcRn inhibition, but mixed data tempers confidence in its superiority. See why IMVT stock is a Hold. - Immunovant is rated Hold as IMVT-1402 advances through five potentially…
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT)... NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder…
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
The National Law Review IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)--$IMVT--Schall, Br
Bronstein, Gewirtz & Grossman, LLC Initiate an Investigation into Allegations Against Immunovant, Inc. (IMVT) And Encourages Shareholders to Reach Out
Sunday, 11 October 2026 01:00 PM On September 23, 2026, Immunovant announced that its proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus did not achieve statistical significance on its primary endpoint. The company said…
Immunovant (NASDAQ:IMVT) CEO Sells $119,589.66 in Stock
Posted by Kim Johansen on Oct 8th, 2026 Shares of NASDAQ:IMVT opened at $32.04 on Thursday. The company has a market capitalization of $6.62 billion, a price-to-earnings ratio of -11.36 and a beta of 0.84. The firm’s 50 day simple moving…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- accessnewswire.com2
- natlawreview.com2
- businesswire.com1
- markets.businessinsider.com1
- prnewswire.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.